AMENDMENT TO STOCK OPTION AGREEMENTSStock Option Agreement • March 7th, 2024 • Lineage Cell Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
This AMENDMENT TO STOCK OPTION AGREEMENTS (this “Amendment”), is made and entered into as of December 4, 2023 (the “Amendment Date”), by and between Lineage Cell Therapeutics, Inc., a California corporation (the “Company”), and Dr. Gary S. Hogge, an individual (“Dr. Hogge”).
November 30, 2023 Gary S. Hogge, DVM, PhD. c/o Lineage Cell Therapeutics, Inc. Carlsbad, CA 92008 Re: Separation, Release and Consulting Agreement Dear Gary:Separation, Release and Consulting Agreement • March 7th, 2024 • Lineage Cell Therapeutics, Inc. • Biological products, (no disgnostic substances)
This Separation, Release and Consulting Agreement (this “Agreement”) summarizes the terms and conditions of the separation, release and consulting agreement that Lineage Cell Therapeutics, Inc. (“Lineage”) is offering you in connection with your employment termination.
